• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB
Click for more information
2.78% 35.0¢

DIMERIX LIMITED - News & Media

Market Cap $192.3M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.More

Articles & Videos

Dimerix gains NMPA approval for IND, opening doors to global phase three tudy on FSGS Treatment

Dimerix (ASX:DXB) has secured approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its IND application.

28 Nov 2023 12:50 (AEDT)

Dimerix secures $10.7m upfront payment from Advanz Pharma

Dimerix (ASX:DXB) has received an initial upfront payment of A$10.7 million as part of its licensing agreement with Advanz Pharma.

06 Nov 2023 15:40 (AEDT)

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

Dimerix (ASX:DXB) is set to pocket $2.8 million as a prepayment of a research and development (R&D) tax incentive claim.

17 Feb 2023 10:56 (AEDT)

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

Dimerix (ASX:DXB) has received the green light to include paediatric patients in its ACTION3 study of focal segmental glomerulosclerosis (FSGS).

12 Jan 2023 09:16 (AEDT)



(20min delay)
Last
35.0¢ 		Change
-0.010(2.78%) 		Mkt cap ! $192.3M
Open High Low Value Volume
36.0¢ 37.0¢ 34.0¢ $1.977M 5.663M

Buyers (Bids)

No. Vol. Price($)
9 1445485 34.5¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 24999 1
View Market Depth
Last trade - 16.10pm 06/05/2024 (20 minute delay) ?
Last
34.5¢ 		  Change
-0.010 ( 4.14 %)
Open High Low Volume
36.5¢ 37.0¢ 34.0¢ 2600347
Last updated 15.59pm 06/05/2024 ?
DXB (ASX) Chart

Top Stories

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Westpac Banking Corporation has reported a 16 percent drop in net profit (to $3.342 billion) for the first half of the 2024 financial year compared to the same time last year.
Tamboran is listing on the NYSE, and Wall Street is paying attention If you needed evidence that Tamboran Resources is bullish on the NT's Beetaloo Basin, look no further than its decision to list on the NYSE.
Sold out signs go up for RIU Resources Roundup in Sydney More than 115 companies will be participating in this year's RIU Resources Roundup in Sydney.
Maiden drilling at West Arunta hints at major IOCG system for Rincon Rincon Resources believes that drill core picked up from a maiden program of work at its West Arunta project in Western Australia indicates potential for a major iron oxide copper gold deposit.
Mantle Minerals to kick off drilling at Mt Berghaus in WA Mantle Minerals (ASX:MTL) has announced it's kicking off a 122-hole drill run on-site its Mt Berghaus acreage in Western Australia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.